Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under renewed focus after the FDA approved extended dosing intervals for EYLEA HD, impacting its valuation. The stock currently trades at $763.04, with a 1-year return of 33.94%, and a most popular valuation narrative suggesting it's 12.7% undervalued with a fair value of $873.78. This valuation is supported by its broad pipeline, including immunology, oncology, genetic medicines, and obesity treatments, though competitive pressures and R&D costs present risks.
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under valuation scrutiny after the FDA approved extended dosing for EYLEA HD, easing treatment schedules. Despite a 34% one-year total shareholder return, the stock's year-to-date performance is slightly negative. Simply Wall St's analysis suggests REGN is modestly undervalued at $763.04, with a fair value pegged at $873.78, though its P/E ratio is higher than the US Biotech average.
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Evotec SE has nominated Dieter Weinand as the new Chairman of its Supervisory Board, with his election proposed for the Annual General Meeting on June 11, 2026. Weinand, an industry veteran with over 30 years of global pharmaceutical leadership experience, will succeed Prof. Dr. Iris Löw-Friedrich. This strategic appointment aims to bolster Evotec's commercial execution, strategic partnerships, and profitability, supporting its ongoing transformation.
FDA approves expanded EYLEA HD dosing intervals
Regeneron Pharmaceuticals' EYLEA HD (aflibercept) injection 8 mg has received expanded FDA approval for extended dosing intervals in wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This allows for administration up to every 20 weeks following one year of successful response, building on previous approvals. The decision is based on 96-week data from the PULSAR and PHOTON trials, demonstrating sustained efficacy and safety with extended intervals.
Genome Editing Market Is Going to Boom |• CRISPR Therapeutics • Editas Medicine
Worldwide Market Reports has published a comprehensive analysis titled "Genome Editing Market Size and Forecast 2026-2033," predicting significant growth in the genome editing sector. The report, based on extensive research, details market drivers, challenges, opportunities, and competitive landscapes, featuring key players like CRISPR Therapeutics and Editas Medicine. It offers crucial insights for stakeholders, covering market segmentation by types and applications, regional trends, and forecasts to aid investment decisions.
Regeneron And TriNetX Partner To Expand Global Genomic And EHR Linked Data Platform
Regeneron and TriNetX have announced a strategic collaboration to integrate large-scale genomic and proteomic datasets with TriNetX's extensive global network of electronic health records. This partnership aims to accelerate drug discovery and empower AI-driven digital health innovation by expanding Regeneron's existing EHR-linked database. Regeneron will also invest up to $200 million in TriNetX as part of this collaboration.
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Tritonpoint Wealth LLC significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 70.0% in the fourth quarter, selling 1,938 shares and holding 829 shares worth approximately $640,000. This comes as Regeneron has seen positive developments, including FDA approval for EYLEA HD with extended dosing, a strategic collaboration with TriNetX for AI-driven drug discovery, and increased Wall Street optimism following an earnings beat and a dividend hike. The company's stock shows strong institutional ownership and a "Moderate Buy" average rating from analysts.
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC
Sovran Advisors LLC significantly reduced its stake in Regeneron Pharmaceuticals (REGN) by 22.6% in the fourth quarter, selling 2,519 shares. This comes amidst other institutional investors modifying their holdings and notable insider selling by executives. Despite these sales, Regeneron reported strong Q4 earnings, received FDA approval for EYLEA HD with extended dosing, increased its dividend, and maintains a "Moderate Buy" consensus analyst rating.
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition
Regeneron Pharmaceuticals received FDA approval to extend the dosing interval for EYLEA HD for wet age-related macular degeneration and diabetic macular edema up to every 20 weeks, based on two years of efficacy and safety data. This label update offers more flexibility for patients and physicians and strengthens Regeneron's competitive position against rivals like Roche’s Vabysmo and Novartis’ Beovu, although the company still faces market pressures from biosimilars and alternative therapies. Investors should monitor real-world adoption rates, payer responses, and competitive reactions to gauge the long-term impact of this development.
REGN Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial analysis of Regeneron Pharmaceuticals Inc (REGN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. It highlights that Sanofi is REGN's largest revenue contributor, and the company maintains strong gross, operating, and net margins, outperforming competitors like GSK and SNY in gross margin.
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals
Allspring Global Investments increased its stake in Regeneron Pharmaceuticals by 40.1% in Q4 2025, now owning 37,559 shares valued at $29.157 million. This move signals the investment firm's continued confidence in Regeneron's growth prospects, innovative drug pipeline, and ability to deliver long-term shareholder value. Regeneron is highlighted as a leading biotech firm known for its drug discovery and biologic therapies.
InflaRx NV stock: Biotech innovator or high-risk bet?
InflaRx NV, a German clinical-stage biopharmaceutical company listed on Nasdaq, focuses on developing complement system inhibitors to treat inflammatory diseases. Its lead drug, vilobelimab, is in Phase III trials for hidradenitis suppurativa and also targets ANCA-associated vasculitis. While offering significant upside potential due to its innovative pipeline targeting rare diseases, the stock is considered a high-risk bet given its early stage, lack of revenue, dependence on trial success, and exposure to biotech volatility.
Regeneron (REGN) director Ryan sells $77,727 in stock
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) director Arthur F. Ryan sold 96 shares of company stock for $77,727 on April 1, 2026. The sales were made pursuant to a Rule 10b5-1(c) trading plan. The biotechnology giant, which remains undervalued and has a "GREAT" financial health score, also recently announced a collaboration with TriNetX and received FDA approval for extended dosing intervals for its EYLEA HD treatment.
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of common stock on April 1, 2026, through open-market transactions. These sales, executed in small tranches at prices ranging from $771.32 to $779.71 per share, were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2025. Following these transactions, Ryan directly holds 17,603 shares of Regeneron stock.
Bragar Eagel & Squire, P.C. Urges Ostin and NuScale Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
Bragar Eagel & Squire, P.C. has reminded investors of Ostin Technology Group Co., Ltd. (NASDAQ:OST) and NuScale Power Corporation (NYSE:SMR) about upcoming lead plaintiff deadlines for class action lawsuits. The firm is urging investors who have experienced significant losses to contact them. The lawsuits allege securities fraud, with Ostin's case involving a scheme to artificially inflate stock price and NuScale's case concerning misleading statements about commercialization strategy.
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In Japan - Learn Why
Regeneron Pharmaceuticals and Sanofi recently secured approval in Japan for Dupixent to treat moderate-to-severe bullous pemphigoid, marking a significant advancement as the first targeted non-immunosuppressant therapy for this rare skin disease. While this expands Dupixent's immunology portfolio, the article emphasizes that Regeneron's near-term investment narrative remains heavily influenced by the performance of its EYLEA franchise amidst competitive and pricing pressures. Investors should consider how this new approval reinforces or redefines their outlook on Regeneron's financial forecasts and its reliance on mature assets versus future growth opportunities.
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In Japan - Learn Why
Regeneron Pharmaceuticals and Sanofi received approval from Japan’s Ministry of Health for Dupixent to treat moderate-to-severe bullous pemphigoid, marking its seventh Japanese indication. This approval introduces a new treatment option for a rare skin disease and reinforces Regeneron's immunology focus. However, the article notes that while significant, this development might not outweigh the immediate financial impact of defending EYLEA against competition or broader drug pricing pressures, which remain key factors for investors.
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Regeneron Pharmaceuticals (NASDAQ: REGN) is undergoing a significant transformation, moving beyond its core immunology and ophthalmology franchises to aggressively enter the oncology and obesity markets. The company, known for its science-first approach and internal innovation, is navigating the challenges of biosimilar competition and shifting regulatory landscapes while leveraging its robust R&D and strong balance sheet for future growth. Key catalysts include upcoming data readouts for Fianlimab in oncology and advancements in its obesity and gene therapy programs.
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings
Aberdeen Group plc increased its holdings in Regeneron Pharmaceuticals (NASDAQ: REGN) by 6.8% in Q4 2025, now owning 161,738 shares valued at $124.84 million. This move indicates strong confidence in Regeneron's financial stability, growth potential, and innovative drug pipeline, with the biotech firm expected to release its Q1 2026 financial results soon.
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Aberdeen Group plc increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the fourth quarter, now holding 161,738 shares valued at approximately $124.84 million. Other institutional investors also adjusted their positions, with institutional investors and hedge funds collectively owning 83.31% of the company's stock. Regeneron Pharmaceuticals announced a quarterly dividend increase and reported earnings that beat analyst expectations.
IPSC Therapy Market Booming with Rapid Growth Through 2033 | Fate Therapeutics • Bluebird Bio • Celyad
Coherent Market Insights has published a report titled "iPSC Therapy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report offers an in-depth analysis of market competition, geographic distribution, and growth potential, covering industry performance, success factors, risk assessment, and financial details. It aims to provide comprehensive insights for entrepreneurs, investors, researchers, and business strategists in the dynamic iPSC Therapy Market.
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD
The FDA has approved extended dosing intervals for Regeneron's Eylea HD, allowing administration up to every 20 weeks for some patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). This decision follows the successful two-year results from the PULSAR and PHOTON trials, which demonstrated sustained efficacy and safety. The approval provides greater flexibility in treatment schedules, benefiting patients who have responded well to treatment.
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD
The FDA has approved extending the dosing intervals for Regeneron's Eylea HD up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) who have shown a successful response after one year. This update, based on 96-week data from the PULSAR and PHOTON trials, allows for individualized treatment plans, offering the broadest dosing range for an injectable anti-VEGF treatment. Regeneron is also awaiting FDA review for an Eylea HD prefilled syringe.
[Form 4] Blue Bird Corp Insider Trading Activity
Kevin S. Penn, a director at Blue Bird Corp (BLBD), reported the acquisition of 2,297 restricted stock units (RSUs) on April 1, 2026, increasing his direct holdings to 6,396 shares. The RSUs vest on March 31, 2027, with accelerated vesting under specific conditions like a change in company control or termination of service due to death, disability, or completion of term. This transaction was reported via a Form 4 filing and does not involve any cash payment.
[Form 4] AEHR TEST SYSTEMS Insider Trading Activity
Aehr Test Systems VP Alistair N. Sporck reported two insider transactions: a tax withholding of 298 shares at $44.32 to cover restricted stock unit vesting and a purchase of 1,963 shares at $6.6725 through the company's Employee Stock Purchase Plan, held indirectly by a trust. These transactions are described as routine and do not represent open market sales. Following these activities, Sporck directly holds 24,855 shares and indirectly holds 7,177 shares through a trust.
Incyte Corporation (INCY) stock price, news, quote and history
This page provides comprehensive information on Incyte Corporation (INCY) stock, including its current price, historical data, key statistics, and company overview. It details Incyte's biopharmaceutical operations, its various therapeutic products, and pipeline projects. The article also includes performance overviews, analyst insights, earnings trends, and valuation measures for INCY, alongside comparisons to similar biotechnology companies.
Takeda Pharmaceuticals to lay off 247 employees in Massachusetts
Takeda Pharmaceuticals, the largest biopharma employer in Massachusetts, will lay off 247 employees in Cambridge starting in July as part of a restructuring plan to cut $1.3 billion in costs. The company cites high taxes, climate mandates, and an unfriendly business environment in Massachusetts as reasons, with an additional 387 job cuts planned in other states. This move is contributing to concerns about the state's ability to retain businesses and talent amid rising costs and regulatory challenges.
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx.
Regeneron Pharmaceuticals plans to invest up to $200 million in Trinetx as part of a strategic partnership. This initiative aims to enhance cooperation in medical data and advance innovation in precision medicine. The investment is expected to deepen the collaboration between both companies.
Replimune, Grace among biotechs with April PDUFA dates
The FDA has at least eight PDUFA dates scheduled for April, including a decision on an oncolytic virus from Replimune Group Inc. While the Center for Biologics Evaluation and Research (CBER) had two decisions planned for April, the ruling on Orca-T from Orca Biosystems Inc. has been delayed to July 6. The article notes that Orca Biosystems updated CMC data in response to an FDA request.
Regeneron partners with TriNetX for health data access By Investing.com
Regeneron Pharmaceuticals Inc. is collaborating with TriNetX to access de-identified electronic health record data from approximately 300 million patients, with an investment of up to $200 million. This partnership grants Regeneron exclusive rights to connect genomic and proteomic data to TriNetX’s phenotypic data network, aiming to enhance drug development and digital health solutions. Regeneron's stock is trading near its 52-week high, and InvestingPro analysis suggests it is currently undervalued.
Onconetix (STU:J4T1) Cyclically Adjusted Price-to-FCF : (As of Apr. 02, 2026)
This article explains the concept of Cyclically Adjusted Price-to-FCF (CAPFCF) as applied to Onconetix (STU:J4T1). It highlights that due to insufficient historical data, GuruFocus cannot calculate the CAPFCF for Onconetix. The article details what CAPFCF is, how it differs from regular Price-to-Free-Cash-Flow, and lists related financial terms.
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
TriNetX and Regeneron Pharmaceuticals have announced a strategic collaboration allowing Regeneron exclusive access to TriNetX's network of approximately 300 million de-identified patient health records. This partnership will enable Regeneron to expand its world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, fostering drug discovery, development, and the creation of AI-powered digital health solutions. Regeneron will also invest up to $200 million in TriNetX as part of this agreement.
300 million health records: Regeneron puts up to $200M into TriNetX
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a strategic collaboration with TriNetX, involving an investment of up to $200 million, to access TriNetX's de-identified electronic health record (EHR) network, which contains approximately 300 million patient records globally, including 170 million in the U.S. This partnership will enable Regeneron to expand its Genetics Center's (RGC) EHR-linked database and enhance its AI training algorithms for digital health solutions. The collaboration aims to accelerate drug discovery, development, and the creation of innovative digital health tools, all while adhering to strict privacy laws like HIPAA and GDPR.
[ARS] Bionano Genomics, Inc. SEC Filing
This article reports on an ARS SEC filing by Bionano Genomics, Inc. (BNGO) on April 2, 2026, noting a low filing impact and neutral sentiment. It provides key details about the filing and links to both the company's stock overview and the original SEC EDGAR document. Additionally, it lists recent news and other SEC filings related to Bionano Genomics.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
Shares of Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna fell after reports suggested the U.S. might impose up to 100% tariffs on imported branded and patented drugs. This potential move targets pharmaceutical companies that have not agreed to lower drug prices in the United States, prompting a significant sell-off in the sector. The article notes that stock market overreactions can create buying opportunities for high-quality stocks.
Regeneron says it expects to avoid new US pharma tariffs
Drugmaker Regeneron expects to be excluded from new U.S. government tariffs targeting pharmaceutical companies that have not agreed to lower drug prices. The company anticipates announcing a deal with the Trump administration soon to reduce prescription drug prices for Medicaid and cash-paying patients. Regeneron is currently the sole company among 17 large pharmaceutical firms that received letters from President Trump in July that has yet to sign such an agreement.
Regeneron says it expects to avoid new US pharma tariffs
Regeneron Pharmaceuticals (REGN) anticipates it will not be affected by new US pharmaceutical tariffs. This brief statement was released by Reuters via TradingView News.
U.S. burn emergency stockpile gets NexoBrid in $197M BARDA pact
Vericel (NASDAQ:VCEL) has secured a ten-year contract with BARDA, valued at up to $197 million, for the procurement and advanced development of its severe burn treatment, NexoBrid. This agreement includes an initial $35 million base period, with approximately $10 million allocated for procurement and Vendor Managed Inventory (VMI) over the next 12 months, aimed at expanding the U.S. Strategic National Stockpile. The contract also covers the design of a U.S. manufacturing facility and the development of a room-temperature stable formulation and a blast trauma indication for NexoBrid.
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com
The FDA has approved extended dosing intervals for Regeneron's EYLEA HD treatment, allowing some patients with wet age-related macular degeneration and diabetic macular edema to receive injections as infrequently as every 20 weeks. This approval is based on 96-week data from the PULSAR and PHOTON trials, showing strong clinical results and dosing flexibility for individual patient response. Regeneron, a $77.25 billion biotechnology company, maintains solid financial footing and its stock is considered undervalued according to InvestingPro analysis.
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock
Shares of Regeneron Pharmaceuticals (REGN) saw an increase after financial commentator Jim Cramer publicly endorsed the stock. Cramer's positive remarks included calling Regeneron a good stock for investment. This surge highlights the potential impact of high-profile financial endorsements on stock performance.
Catheter Precision puts heart device business up for sale, pivots to aviation
Catheter Precision (NYSE American: VTAK) announced on April 2, 2026, that it has engaged a strategic advisor to sell its cardiac electrophysiology business, including its LockeT and VIVO medical devices. This move aims to monetize existing FDA and CE marked assets while allowing the company to sharpen its focus on its high-growth Flyte aviation platform, transforming into a "pure-play aviation business." CEO David Jenkins expressed belief that larger companies could better realize the value of their cardiac portfolio, which is not currently reflected in VTAK's market capitalization.
Abivax (WBO:ABVX) Shiller PE Ratio : (As of Apr. 02, 2026)
This article from GuruFocus provides a detailed explanation and historical data for Abivax (WBO:ABVX)'s Shiller PE Ratio as of April 2, 2026. It highlights the calculation methodology for the Shiller PE Ratio, its comparison to the regular PE Ratio, and its application in assessing valuation for cyclical businesses. The article also provides historical data trends, industry comparisons, and related financial terms, noting that some detailed features are exclusive to premium members.
Regeneron (REGN) and Sanofi announce Dupixent approval in Japan to treat bullous pemphigoid
Regeneron (REGN) and Sanofi announced that Dupixent has received approval in Japan for the treatment of bullous pemphigoid. This marks the first approval of Dupixent for an autoimmune disease and the first and only approved drug in Japan for this specific rare and debilitating skin condition. The approval is based on positive data from a Phase 3 trial and real-world evidence.
Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN
Moody Lynn & Lieberson LLC recently purchased a new position in Regeneron Pharmaceuticals (NASDAQ:REGN), acquiring 3,350 shares valued at approximately $2.586 million. This move is part of broader institutional interest, with other major firms like State Street Corp and Dodge & Cox also increasing their holdings. The biopharmaceutical company has seen positive sentiment from Japan's approval of Dupixent and Piper Sandler initiating coverage with an "overweight" rating.
Piper Sandler initiates Regeneron stock with Overweight rating
Piper Sandler initiated coverage on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) with an Overweight rating and a price target of $875.00, citing the company as a top-tier large-cap biotech with a durable growth engine anchored by Dupixent and Eylea HD. The firm believes the market undervalues Regeneron's core franchise and high-potential pipeline assets, which include new developments like positive Phase 3 trial results for its obesity drug olatorepatide. Other analysts including Jefferies, TD Cowen, Truist Securities, and Barclays have also expressed confidence in Regeneron, raising price targets and maintaining Buy or Overweight ratings based on similar expectations for its product pipeline.
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena
This article highlights Regeneron Pharmaceuticals (NASDAQ: REGN) as a strong contender in the biotech sector, drawing insights from Motley Fool analysts. While the article presents an opportunity to explore Regeneron, it also promotes Motley Fool's Stock Advisor, which did not include Regeneron in its top 10 stock picks. The content emphasizes the potential for significant returns from their recommended stocks.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Regeneron Pharmaceuticals Inc. (REGN) saw its stock rise by 3.12% to $772.64 on Tuesday, outperforming the broader market indices, including the S&P 500 and Dow Jones Industrial Average. This marked the second consecutive day of gains for the company's shares. The article highlights REGN's strong performance in a generally positive trading session for the stock market.
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Truist Financial recently lowered its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $818 to $801, while maintaining a "buy" rating, indicating a modest 4.4% upside. Despite this somewhat pessimistic revision, Regeneron generally holds a "Moderate Buy" consensus rating among analysts, with a wide range of individual price targets. The company recently surpassed quarterly earnings and revenue estimates, but has also seen significant insider selling activity.
Truist cuts Regeneron stock price target on biosimilar concerns
Truist Securities has lowered its price target for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to $801 from $818, while maintaining a Buy rating. The adjustment reflects concerns over the Eylea franchise's positioning and the evolving biosimilar landscape, with 2026 being a critical year for biosimilar entry. Despite the target cut, InvestingPro analysis suggests the stock remains undervalued with a Fair Value of $929.
SNP Genotyping and Analysis Market to See Booming Growth
The SNP Genotyping and Analysis Market is anticipated to experience significant growth from 2026 to 2033, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscapes. The report aims to provide stakeholders with actionable insights for informed, data-driven decisions amidst global market dynamics.
